In line with the ESC mission, newly presented content is made available to all for a limited time (4 months for ESC Congress, 3 months for other events). ESC Professional Members, Association Members (Ivory & above) benefit from year-round access to all the resources from their respective Association, and to all content from previous years. Fellows of the ESC (FESC), and Professionals in training or under 40 years old, who subscribed to a Young Combined Membership package benefit from access to all ESC 365 content from all events, all editions, all year long. Find out more about ESC Memberships here.
Association of M235T polymorphism of angiotensinogen gene and lipid parameters in heart failure patients with type 2 diabetes mellitus.
The ESC does not have the copyright for the slides and video of this presentation
1L.T.Malaya Institute of Therapy, Department of Clinical Pharmacology and Pharmagenetics of non-communicable diseases - Kharkiv - Ukraine
European Journal of Heart Failure
Background. Polymorphism of angiotensinogen (ATG) gene M235T could be associated with coronary artery disease (CAD). Dyslipidemia have been reported as one of the main pathophysiological mechanism contributing to CAD. It’s well known that arterial hypertension and CAD play an important role in unfavorable course of heart failure with preserved ejection fraction (HFpEF) development. On the other hand, the association of M235T polymorphism of ATG gene and lipid parameters in heart failure patients with type 2 diabetes mellitus (T2DM) is not well researched.
Purpose. To investigate the parameters of lipid metabolism in diabetic and non-diabetic subjects carrying different types of M235T polymorphism of ATG with HFpEF.
Methods. One hundred and thirty-three patients (58 males and 75 females; mean age 61,78±9,7 years) with HFpEF were examined. One hundred patients were carriers of 235T allele (MT + TT genotypes), 33 patients were homozygous carriers of 235M allele of M235T polymorphism of ATG. T2DM had 83 patients and 49 were non-diabetic patients. By using of polymerase chain reaction, different genotypes of M235T polymorphism of ATG were determined. The lipid metabolism parameters were performed by using kits of reagents "NUMAN" (Germany). Continuous variables as median (25th, 75th percentile) are expressed. Mann-Whitney U test was used for nonparametric comparisons. All statistical tests were 2-tailed and p<0,05 was considered statistically significant.
Results. In the group of T2DM subjects levels of serum total cholesterol ((6,00 (5,00 : 6,80) vs to 5,10 (4,30 : 5,90) mmol/l), very low-density lipoprotein-cholesterol ((0,92 (0,62 : 1,33) vs 0,69 (0,47 : 0,83) mmol/l) and triglycerides ((2,10 (1,50 : 2,95) vs 1,6 (1,15 : 1,85) mmol/l, respectively) were increased comparing with the group of non-diabetic patients, carrying the 235T allele of M235T polymorphism, (p<0,005). No significant differences in lipids parameters such as levels of serum total cholesterol ((5,85 (4,57 : 7,05) vs to 5,65 (4,7 : 6,77) mmol/l), very low-density lipoprotein-cholesterol ((0,88 (0,67 : 1,15) vs 0,85 (0,55 : 0,98) mmol/l) and triglycerides ((2,05 (1,80 : 2,57) vs 1,9 (1,22 : 2.20) mmol/l) were found in M235M carriers with T2DM and without it, respectively, (p > 0,05).
Conclusions: The most unfavorable lipid parameters profile had diabetic patients with HFpEF and MT + TT genotypes of M2335T polymorphism of ATG.
ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.
Our mission: To reduce the burden of cardiovascular disease